"Adrenomedullin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 52-amino acid peptide with multi-functions. It was originally isolated from PHEOCHROMOCYTOMA and ADRENAL MEDULLA but is widely distributed throughout the body including lung and kidney tissues. Besides controlling fluid-electrolyte homeostasis, adrenomedullin is a potent vasodilator and can inhibit pituitary ACTH secretion.
| Descriptor ID |
D053607
|
| MeSH Number(s) |
D06.472.699.077 D12.644.548.017
|
| Concept/Terms |
PAMP(1-20)NH2- PAMP(1-20)NH2
- Proadrenomedullin N-Terminal 20 Peptide
- Proadrenomedullin N Terminal 20 Peptide
- Proadrenomedullin (1-20)
|
Below are MeSH descriptors whose meaning is more general than "Adrenomedullin".
Below are MeSH descriptors whose meaning is more specific than "Adrenomedullin".
This graph shows the total number of publications written about "Adrenomedullin" by people in this website by year, and whether "Adrenomedullin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 7 | 5 | 12 |
| 2018 | 15 | 5 | 20 |
| 2019 | 3 | 1 | 4 |
| 2020 | 3 | 0 | 3 |
| 2021 | 7 | 0 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Adrenomedullin" by people in Profiles.
-
Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19. Lab Med. 2021 Sep 01; 52(5):493-498.
-
Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. Int J Infect Dis. 2021 Oct; 111:211-218.
-
Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: A prospective cohort study. J Crit Care. 2021 12; 66:173-180.
-
Pooled analysis of mid-regional pro-adrenomedullin values in COVID-19 patients with critical illness. Intern Emerg Med. 2021 09; 16(6):1723-1725.
-
MR-proAdrenomedullin as a predictor of renal replacement therapy in a cohort of critically ill patients with COVID-19. Biomarkers. 2021 Jul; 26(5):417-424.
-
Mid-regional pro-adrenomedullin as a supplementary tool to clinical parameters in cases of suspicion of infection in the emergency department. Expert Rev Mol Diagn. 2021 04; 21(4):397-404.
-
MR-proADM as prognostic factor of outcome in COVID-19 patients. Sci Rep. 2021 03 04; 11(1):5121.
-
MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur J Clin Invest. 2021 May; 51(5):e13511.
-
High value of mid-regional proadrenomedullin in COVID-19: A marker of widespread endothelial damage, disease severity, and mortality. J Med Virol. 2021 05; 93(5):2820-2827.
-
Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study. PLoS One. 2021; 16(2):e0246771.